Evozyne
Marc Yoskowitz currently serves as Chief Executive Officer of Evozyne and holds non-executive director positions at Mallinckrodt Pharmaceuticals and Mereo BioPharma, where involvement includes membership in the R&D Committee. Previously, Marc was a non-executive director at Endo, chairing the Compliance Committee and participating in the Nomination and Governance Committee as well as the Product Portfolio Committee. Additional experience includes advisory roles at Broken String Biosciences Ltd, Paragon Biosciences, and Mahana Therapeutics, as well as serving as Chief Strategy Officer and Executive Vice President at Tempus Life Sciences. Prior roles include Senior Vice President at Pfizer and Hospira, overseeing significant strategy and business operations. Educational credentials encompass a JD from Columbia Law School and a BA from Washington University in St. Louis.
This person is not in any teams
This person is not in any offices
Evozyne
1 followers
Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. By amplifying a protein’s function based on the rules of nature, we address complex, high-impact problems. From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world.